Market research
ATX.AU Amplia Therapeutics Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- Not available
- Beta
- -0.33
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000023822
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- Not available
- Beta
- -0.33
About
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATX.AU discussion.
5 years, 6 months ago
Amplia Therapeutics Limited is currently in a long term downtrend where the price is trading 7.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Amplia Therapeutics Limited's total revenue rose by 2426.2% to $34K since the same quarter in the previous year.
Its net income has increased by 42.3% to $-511K since the same quarter in the previous year.
Finally, its free cash flow grew by 57.9% to $-469K since the same quarter in the previous year.
Based on the above factors, Amplia Therapeutics Limited gets an overall score of 4/5.